Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: ErbB signaling pathway (mmu04012)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
Abl1
KLA  ATP  ATP+KLA
 AK083248 adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630031E05 product:v-abl Abelson murine leukemia oncogene 1, full insert sequence. [AK083248] KLA 1.07 1.07 .92 1.01 .98 1.07 .98
ATP .98 .99 .94 .90 .99 1.07 1.04
KLA/ATP 1.04 1.01 1.03 .98 .97 .95 .99
Abl1
KLA  ATP  ATP+KLA
 NM_009594 c-abl oncogene 1, receptor tyrosine kinase (Abl1), transcript variant 2, mRNA [NM_009594] KLA .63 .62 .65 .71 .96 1.17 1.05
ATP 1.01 1.16 1.03 1.14 1.12 .98 .98
KLA/ATP .66 .64 .67 .73 .84 .90 1.05
Abl2
KLA  ATP  ATP+KLA
 NM_009595 v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene) (Abl2), mRNA [NM_009595] KLA 1.26 1.26 1.10 1.05 .90 1.02 1.10
ATP 1.01 1.21 2.17 2.69 2.85 1.53 1.35
KLA/ATP 1.23 1.31 1.44 1.47 2.45 1.54 1.39
AK088985
KLA  ATP  ATP+KLA
 AK088985 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430034J06 product:unclassifiable, full insert sequence. [AK088985] KLA .99 1.07 .92 .88 .96 1.02 .91
ATP 1.03 .86 .92 .85 1.13 1.00 .93
KLA/ATP .95 1.08 .97 .85 .83 .96 .89
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Areg
KLA  ATP  ATP+KLA
 NM_009704 amphiregulin (Areg), mRNA [NM_009704] KLA 1.06 1.06 1.04 1.18 1.02 .98 1.00
ATP 1.02 1.17 1.49 3.23 2.87 1.85 1.05
KLA/ATP 1.03 1.06 1.33 1.62 1.47 1.46 1.16
Bad
KLA  ATP  ATP+KLA
 AK029400 0 day neonate head cDNA, RIKEN full-length enriched library, clone:4833429M11 product:Bcl-associated death promoter, full insert sequence. [AK029400] KLA 1.15 1.22 1.26 1.31 1.40 1.67 1.59
ATP .95 1.06 1.12 1.06 .78 .89 1.27
KLA/ATP 1.25 1.39 1.33 1.29 1.11 .91 1.38
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Btc
KLA  ATP  ATP+KLA
 NM_007568 betacellulin, epidermal growth factor family member (Btc), mRNA [NM_007568] KLA .98 1.04 1.01 1.00 1.04 1.00 1.01
ATP 1.00 1.00 .98 1.02 1.07 1.01 .96
KLA/ATP 1.01 1.01 .98 .98 1.00 .98 1.01
Camk2a
KLA  ATP  ATP+KLA
 NM_177407 calcium/calmodulin-dependent protein kinase II alpha (Camk2a), transcript variant 2, mRNA [NM_177407] KLA .98 .97 .98 .95 .97 1.02 .97
ATP .98 1.11 1.02 .89 .94 .89 .82
KLA/ATP .99 .95 1.02 .88 .88 .87 .87
Camk2b
KLA  ATP  ATP+KLA
 NM_007595 calcium/calmodulin-dependent protein kinase II, beta (Camk2b), mRNA [NM_007595] KLA 1.09 1.28 1.42 1.41 1.37 1.24 .68
ATP .94 .87 .95 .91 .67 .44 .48
KLA/ATP 1.16 1.24 1.40 1.13 1.14 .81 .49
Camk2d
KLA  ATP  ATP+KLA
 AK032524 adult male olfactory brain cDNA, RIKEN full-length enriched library, clone:6430579P05 product:calcium/calmodulin-dependent protein kinase II, delta, full insert sequence. [AK032524] KLA 1.31 1.45 1.42 1.21 1.34 1.18 1.16
ATP 1.04 1.29 1.39 1.24 .94 .91 1.22
KLA/ATP 1.46 1.64 1.42 1.24 1.00 .93 1.10
Camk2d
KLA  ATP  ATP+KLA
 NM_001025439 calcium/calmodulin-dependent protein kinase II, delta (Camk2d), transcript variant 1, mRNA [NM_001025439] KLA 1.76 1.75 1.72 1.89 1.47 1.55 1.24
ATP 1.06 1.06 .93 1.01 1.22 .98 2.28
KLA/ATP 1.84 1.78 1.40 1.57 1.07 .60 1.97
Camk2g
KLA  ATP  ATP+KLA
 NM_178597 calcium/calmodulin-dependent protein kinase II gamma (Camk2g), transcript variant 1, mRNA [NM_178597] KLA .23 .24 .23 .44 .70 .73 .70
ATP .91 .85 1.07 .86 .58 .59 .95
KLA/ATP .22 .20 .35 .25 .54 .59 .71
Cbl
KLA  ATP  ATP+KLA
 NM_007619 Casitas B-lineage lymphoma (Cbl), mRNA [NM_007619] KLA 1.23 1.22 1.54 1.84 2.25 2.58 2.75
ATP 1.04 1.12 1.07 1.53 1.55 2.12 3.23
KLA/ATP 1.23 1.20 1.22 1.44 1.31 1.88 6.28
Cblb
KLA  ATP  ATP+KLA
 AK045005 9.5 days embryo parthenogenote cDNA, RIKEN full-length enriched library, clone:B130018P07 product:hypothetical protein, full insert sequence. [AK045005] KLA 1.16 1.11 1.15 1.10 1.16 .98 .93
ATP 1.16 1.23 .98 1.28 1.34 .73 1.55
KLA/ATP 1.26 1.60 1.64 1.23 1.01 .91 1.05
Cblb
KLA  ATP  ATP+KLA
 AK084162 12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230004I05 product:unclassifiable, full insert sequence. [AK084162] KLA .97 .98 1.02 1.01 .84 1.02 1.03
ATP 1.03 1.02 .98 1.09 1.05 .96 .96
KLA/ATP 1.07 .95 .91 .98 .98 1.01 1.00
Cblc
KLA  ATP  ATP+KLA
 NM_023224 Casitas B-lineage lymphoma c (Cblc), mRNA [NM_023224] KLA 1.02 .98 1.01 1.02 1.00 .99 1.05
ATP .94 .95 .97 1.04 .99 .97 .99
KLA/ATP 1.00 1.01 .96 .97 .94 .92 .99
Cdkn1a
KLA  ATP  ATP+KLA
 NM_007669 cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a), transcript variant 1, mRNA [NM_007669] KLA 4.72 4.90 4.96 3.73 2.11 1.14 1.02
ATP 1.14 1.52 .95 1.69 1.47 2.21 .50
KLA/ATP 5.99 7.08 3.86 6.37 3.00 2.55 2.05
Cdkn1b
KLA  ATP  ATP+KLA
 NM_009875 cyclin-dependent kinase inhibitor 1B (Cdkn1b), mRNA [NM_009875] KLA .81 .84 .84 .91 .93 .88 .97
ATP .99 1.09 .97 1.06 1.48 .94 .91
KLA/ATP .83 .91 1.04 1.36 1.48 1.06 1.09
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Egf
KLA  ATP  ATP+KLA
 NM_010113 epidermal growth factor (Egf), mRNA [NM_010113] KLA .89 .90 .81 .83 .83 .86 .92
ATP 1.03 1.03 .95 .84 .67 .79 .88
KLA/ATP .86 .86 .77 .77 .69 .78 .83
Egfr
KLA  ATP  ATP+KLA
 NM_007912 epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] KLA 1.10 1.07 1.14 1.11 1.08 1.03 .90
ATP .99 1.00 1.04 .98 .97 1.15 1.14
KLA/ATP 1.07 1.10 1.16 1.08 1.01 .97 .94
Egfr
KLA  ATP  ATP+KLA
 NM_207655 epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] KLA 1.57 1.44 1.47 1.31 .96 .92 .76
ATP .97 .93 1.10 1.00 1.41 2.97 .86
KLA/ATP 1.44 1.50 1.61 1.30 1.14 1.21 .82
Eif4ebp1
KLA  ATP  ATP+KLA
 NM_007918 eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1), mRNA [NM_007918] KLA .66 .64 .59 .67 .81 .97 .97
ATP .97 .94 1.10 1.05 1.99 1.60 .91
KLA/ATP .62 .61 .68 .68 1.50 1.24 .95
Elk1
KLA  ATP  ATP+KLA
 AK082260 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230030F12 product:ELK1, member of ETS oncogene family, full insert sequence. [AK082260] KLA 1.02 1.01 1.01 .97 1.00 1.03 1.06
ATP 1.02 1.07 1.06 1.03 1.02 1.02 1.00
KLA/ATP 1.08 .99 .97 1.01 1.02 1.06 .95
Erbb2
KLA  ATP  ATP+KLA
 NM_001003817 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (Erbb2), mRNA [NM_001003817] KLA 1.01 1.00 .98 1.01 .98 .99 .97
ATP .99 1.00 1.00 1.00 .96 .98 .99
KLA/ATP 1.00 1.01 1.01 1.02 .96 .98 .97
Erbb3
KLA  ATP  ATP+KLA
 BC049279 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), mRNA (cDNA clone IMAGE:4460595), partial cds. [BC049279] KLA .71 .74 .77 .92 1.26 1.39 1.01
ATP .92 .90 .92 .70 .43 .93 1.08
KLA/ATP .66 .70 .71 .61 .56 1.15 1.29
Erbb3
KLA  ATP  ATP+KLA
 NM_010153 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) (Erbb3), mRNA [NM_010153] KLA .98 .99 .98 .98 .98 1.03 1.01
ATP 1.01 1.00 .95 1.00 .94 .95 1.01
KLA/ATP .98 1.03 .95 .99 .99 .99 .93
Erbb4
KLA  ATP  ATP+KLA
 NM_010154 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (Erbb4), mRNA [NM_010154] KLA 1.06 .98 .93 .99 1.02 .98 .91
ATP 1.01 .97 .93 .96 1.00 1.01 1.01
KLA/ATP .94 .96 1.03 .99 .87 .95 1.02
Ereg
KLA  ATP  ATP+KLA
 AK019057 adult male stomach cDNA, RIKEN full-length enriched library, clone:2210040K03 product:epiregulin, full insert sequence. [AK019057] KLA .97 7.75 .93 .97 .97 .97 1.02
ATP .97 1.05 1.09 .98 .97 1.05 1.06
KLA/ATP 1.03 1.04 1.11 1.09 1.03 .98 .99
Ereg
KLA  ATP  ATP+KLA
 NM_007950 epiregulin (Ereg), mRNA [NM_007950] KLA .98 1.01 1.07 .91 .93 1.00 .97
ATP .95 1.01 .99 .96 1.04 1.11 1.09
KLA/ATP 1.04 1.07 1.01 1.01 1.07 1.01 .99
Frap1
KLA  ATP  ATP+KLA
 NM_020009 FK506 binding protein 12-rapamycin associated protein 1 (Frap1), mRNA [NM_020009] KLA 1.37 1.32 1.46 1.57 1.83 1.29 1.28
ATP 1.12 1.07 .95 .91 .80 .77 1.03
KLA/ATP 1.45 1.51 1.50 1.11 .89 .87 1.01
Gab1
KLA  ATP  ATP+KLA
 NM_021356 growth factor receptor bound protein 2-associated protein 1 (Gab1), mRNA [NM_021356] KLA .83 .95 1.12 1.59 3.13 3.14 1.50
ATP .94 .96 1.12 1.74 2.35 5.20 1.66
KLA/ATP .79 .78 1.32 3.74 3.08 4.44 2.62
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Gsk3b
KLA  ATP  ATP+KLA
 NM_019827 glycogen synthase kinase 3 beta (Gsk3b), mRNA [NM_019827] KLA 1.06 1.03 1.11 1.01 1.26 1.28 1.26
ATP 1.18 1.27 1.15 2.07 2.37 2.32 1.67
KLA/ATP 1.15 1.21 .98 1.50 1.67 2.50 2.99
Hbegf
KLA  ATP  ATP+KLA
 NM_010415 heparin-binding EGF-like growth factor (Hbegf), mRNA [NM_010415] KLA 4.85 5.22 4.43 2.64 1.67 1.05 .85
ATP 1.16 1.29 9.30 21.54 19.63 14.93 4.45
KLA/ATP 5.32 5.51 13.94 26.41 22.89 13.95 5.50
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Map2k4
KLA  ATP  ATP+KLA
 NM_009157 mitogen-activated protein kinase kinase 4 (Map2k4), mRNA [NM_009157] KLA 3.67 3.75 4.23 3.90 3.30 1.87 1.12
ATP 1.05 1.11 1.04 .93 1.16 2.62 1.02
KLA/ATP 3.70 4.13 3.27 4.13 2.98 3.03 1.82
Map2k7
KLA  ATP  ATP+KLA
 BC070467 mitogen activated protein kinase kinase 7, mRNA (cDNA clone MGC:96654 IMAGE:30615302), complete cds [BC070467] KLA .77 .79 .88 .77 .97 .96 1.27
ATP 1.11 1.26 .93 1.19 1.13 1.45 1.16
KLA/ATP .89 .88 .59 .89 .86 1.32 1.28
Map2k7
KLA  ATP  ATP+KLA
 NM_001042557 mitogen-activated protein kinase kinase 7 (Map2k7), transcript variant 1, mRNA [NM_001042557] KLA .96 .95 1.02 .96 .95 1.09 1.19
ATP 1.02 1.07 .88 .97 .93 1.10 1.17
KLA/ATP 1.01 .99 .80 .87 .76 1.21 1.16
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk10
KLA  ATP  ATP+KLA
 AK076990 adult male testis cDNA, RIKEN full-length enriched library, clone:4930597C01 product:mitogen activated protein kinase 10, full insert sequence. [AK076990] KLA 1.03 1.05 .98 1.04 .94 .95 1.02
ATP 1.00 .99 1.06 .97 1.01 .96 .99
KLA/ATP 1.07 1.01 .95 1.05 .82 .95 .87
Mapk10
KLA  ATP  ATP+KLA
 NM_009158 mitogen-activated protein kinase 10 (Mapk10), transcript variant 1, mRNA [NM_009158] KLA .95 1.00 .97 1.01 .99 1.01 .95
ATP 1.01 1.02 .98 1.01 1.04 1.01 .99
KLA/ATP 1.05 .99 1.01 .98 .92 .97 .98
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Mapk8
KLA  ATP  ATP+KLA
 AK162915 adult male spinal cord cDNA, RIKEN full-length enriched library, clone:A330031O19 product:mitogen activated protein kinase 8, full insert sequence [AK162915] KLA .94 .86 .80 .83 .77 .85 .83
ATP 1.08 1.12 .94 .80 .83 .71 .75
KLA/ATP .83 .81 .80 .74 .74 .75 .67
Mapk8
KLA  ATP  ATP+KLA
 AK163829 16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130070A06 product:mitogen activated protein kinase 8, full insert sequence [AK163829] KLA .65 .61 .66 .70 .90 1.02 1.03
ATP .99 .94 1.68 1.44 1.75 1.84 1.10
KLA/ATP .63 .67 1.11 1.00 2.01 1.68 1.15
Mapk8
KLA  ATP  ATP+KLA
 NM_016700 mitogen-activated protein kinase 8 (Mapk8), mRNA [NM_016700] KLA .96 1.00 .94 .96 .94 .99 1.04
ATP 1.01 1.05 1.01 .99 1.03 .98 1.02
KLA/ATP .96 .97 .96 .97 .93 .94 .96
Mapk9
KLA  ATP  ATP+KLA
 NM_016961 mitogen-activated protein kinase 9 (Mapk9), transcript variant 2, mRNA [NM_016961] KLA 1.28 1.37 1.59 1.60 1.61 1.43 1.38
ATP 1.03 .99 .74 .71 .79 1.20 1.01
KLA/ATP 1.53 1.30 1.07 .99 .83 1.10 1.40
Mapk9
KLA  ATP  ATP+KLA
 NM_207692 mitogen-activated protein kinase 9 (Mapk9), transcript variant 1, mRNA [NM_207692] KLA 1.39 1.53 1.69 1.69 1.55 1.44 1.51
ATP .95 .92 .75 .85 .70 1.46 1.17
KLA/ATP 1.37 1.35 .99 1.18 .91 1.22 1.62
Mm.13153
0
KLA  ATP  ATP+KLA
 161086915 Unknown KLA 1.00 1.07 1.14 1.08 .97 1.00 .93
ATP 1.04 .99 1.00 .95 .99 1.02 .90
KLA/ATP 1.08 1.18 1.14 1.16 1.04 1.06 1.08
Mm.13157
2
KLA  ATP  ATP+KLA
 134949023 Unknown KLA 1.04 1.01 .96 .95 .95 1.00 .99
ATP .98 1.02 .99 1.07 .97 .96 1.00
KLA/ATP .96 .88 .91 1.00 1.02 .98 1.05
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.24185
7
KLA  ATP  ATP+KLA
 142347489 Unknown KLA 1.18 1.09 1.27 1.24 1.14 1.18 1.15
ATP 1.10 1.02 1.13 1.16 1.04 1.03 1.11
KLA/ATP 1.17 1.19 1.29 1.21 1.10 1.02 1.19
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.26687
1
KLA  ATP  ATP+KLA
 80978931 Unknown KLA .67 .63 .70 .83 1.66 1.43 1.54
ATP 1.20 1.24 1.22 1.26 1.80 .81 1.02
KLA/ATP .63 .56 .83 1.06 1.26 .70 1.34
Mm.28968
1
KLA  ATP  ATP+KLA
 6754177 Unknown KLA 5.70 5.98 5.26 3.13 1.73 .87 .76
ATP 1.12 1.23 10.71 22.34 24.13 18.42 4.28
KLA/ATP 5.68 6.39 18.15 29.48 26.96 19.85 6.17
Mm.41292
2
KLA  ATP  ATP+KLA
 145966829 Unknown KLA 3.65 3.76 3.75 3.79 3.42 1.75 1.10
ATP 1.11 1.17 1.04 .90 1.37 2.90 1.00
KLA/ATP 3.31 3.97 3.38 3.84 3.04 3.31 2.09
Mm.4387
KLA  ATP  ATP+KLA
 133892666 Unknown KLA .85 .87 .85 .89 .77 .91 1.18
ATP 1.01 1.01 .87 1.07 .75 .86 .93
KLA/ATP .88 .86 .77 .81 .72 .91 .84
Mm.44387
4
KLA  ATP  ATP+KLA
 157817519 Unknown KLA 1.29 1.26 1.17 1.13 1.26 1.49 3.05
ATP 1.02 1.02 1.20 1.05 1.26 1.26 1.81
KLA/ATP 1.32 1.31 1.30 1.11 1.21 1.25 2.73
Mm.44463
KLA  ATP  ATP+KLA
 118129851 Unknown KLA 1.01 .98 .97 1.02 .93 1.06 1.05
ATP .97 1.01 1.04 1.06 1.02 1.08 .97
KLA/ATP 1.02 1.06 .95 1.04 1.09 1.14 1.03
Mm.45825
9
KLA  ATP  ATP+KLA
 116292181 Unknown KLA .84 .86 .91 .85 .98 .98 1.00
ATP 1.05 1.06 .94 .95 1.00 .89 .89
KLA/ATP .92 .84 .87 .93 .91 .92 .82
Mm.47351
0
KLA  ATP  ATP+KLA
 162287332 Unknown KLA 4.46 4.82 5.29 4.00 2.26 1.25 1.10
ATP 1.24 1.72 1.02 2.08 1.66 2.53 .55
KLA/ATP 6.11 7.67 4.29 6.99 3.11 2.86 2.30
Mm.81698
KLA  ATP  ATP+KLA
 158937287 Unknown KLA .95 1.02 1.04 .98 1.01 1.04 1.08
ATP 1.00 1.03 .97 1.00 1.03 .98 .96
KLA/ATP 1.07 1.00 .94 .98 1.03 1.05 .97
Myc
KLA  ATP  ATP+KLA
 NM_010849 myelocytomatosis oncogene (Myc), mRNA [NM_010849] KLA .38 .31 .45 .45 .49 .35 .33
ATP 1.05 1.09 1.72 4.41 1.28 .45 .76
KLA/ATP .37 .30 .44 1.23 .34 .17 .19
Nck1
KLA  ATP  ATP+KLA
 ENSMUST00000116522 ens|non-catalytic region of tyrosine kinase adaptor protein 1 [Source:RefSeq_peptide;Acc:NP_035008] [ENSMUST00000116522] KLA 1.59 1.56 1.35 1.27 1.34 1.04 1.21
ATP 1.25 1.32 1.00 1.18 1.79 1.25 .96
KLA/ATP 2.00 2.22 1.41 1.34 1.21 1.35 1.27
Nck1
KLA  ATP  ATP+KLA
 NM_010878 non-catalytic region of tyrosine kinase adaptor protein 1 (Nck1), mRNA [NM_010878] KLA 6.52 5.82 4.53 2.34 1.72 1.14 1.26
ATP .91 .92 1.07 .68 1.72 2.07 1.15
KLA/ATP 5.62 5.96 5.77 2.46 1.63 1.99 1.86
Nck2
KLA  ATP  ATP+KLA
 NM_010879 non-catalytic region of tyrosine kinase adaptor protein 2 (Nck2), mRNA [NM_010879] KLA 1.72 1.26 1.32 1.00 1.46 1.78 1.50
ATP 1.08 1.05 .84 .59 1.28 1.26 1.17
KLA/ATP 1.68 1.27 1.14 .80 .94 .99 1.91
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Nrg1
KLA  ATP  ATP+KLA
 AK031289 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030402G23 product:unclassifiable, full insert sequence [AK031289] KLA 1.09 1.20 1.09 1.15 1.04 1.03 1.01
ATP .97 1.05 1.00 1.05 1.09 1.89 1.71
KLA/ATP 1.10 1.03 .98 1.13 1.25 1.82 1.52
Nrg1
KLA  ATP  ATP+KLA
 AK083943 12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130067D16 product:unclassifiable, full insert sequence. [AK083943] KLA 1.04 1.05 1.08 1.06 1.10 1.11 1.10
ATP .98 1.01 1.14 1.05 1.15 2.02 1.41
KLA/ATP 1.07 1.01 1.27 1.20 1.13 1.66 1.33
Nrg1
KLA  ATP  ATP+KLA
 NM_178591 neuregulin 1 (Nrg1), mRNA [NM_178591] KLA 1.38 1.33 1.45 1.48 1.42 1.27 1.09
ATP 1.01 1.00 1.10 1.13 1.09 2.46 6.66
KLA/ATP 1.33 1.36 1.45 1.58 1.45 2.26 4.88
Nrg3
KLA  ATP  ATP+KLA
 NM_008734 neuregulin 3 (Nrg3), mRNA [NM_008734] KLA 1.09 1.00 .94 1.01 1.07 1.01 1.00
ATP 1.01 1.08 1.01 1.05 .97 1.00 .95
KLA/ATP 1.10 .99 .99 .99 .98 1.01 1.06
Nrg4
KLA  ATP  ATP+KLA
 NM_032002 neuregulin 4 (Nrg4), mRNA [NM_032002] KLA 1.07 1.13 1.04 1.16 1.10 1.24 1.75
ATP .94 .98 1.00 1.02 1.08 1.14 1.32
KLA/ATP 1.07 1.03 1.08 1.06 1.14 1.34 2.05
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pak3
KLA  ATP  ATP+KLA
 NM_008778 p21 (CDKN1A)-activated kinase 3 (Pak3), mRNA [NM_008778] KLA 1.06 1.02 1.03 1.00 1.06 1.01 1.01
ATP 1.05 1.01 1.03 .97 .98 1.08 1.07
KLA/ATP 1.00 .99 .99 1.03 1.00 1.01 1.08
Pak4
KLA  ATP  ATP+KLA
 NM_027470 p21 (CDKN1A)-activated kinase 4 (Pak4), mRNA [NM_027470] KLA 1.41 1.51 1.62 1.57 1.88 1.26 1.06
ATP 1.13 1.15 1.04 1.21 1.73 1.45 1.03
KLA/ATP 1.58 1.60 1.31 1.65 1.84 1.64 1.40
Pak6
KLA  ATP  ATP+KLA
 AK028788 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732456M09 product:p21 (CDKN1A)-activated kinase 6, full insert sequence. [AK028788] KLA 1.38 1.33 1.40 1.45 1.42 1.49 1.20
ATP .95 .93 1.15 1.21 1.21 1.32 1.10
KLA/ATP 1.33 1.38 1.55 1.44 1.57 1.45 1.36
Pak7
KLA  ATP  ATP+KLA
 AK077967 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030481C12 product:hypothetical protein, full insert sequence. [AK077967] KLA 1.00 1.01 1.07 1.02 .99 1.01 1.05
ATP .93 .95 1.03 1.01 1.02 .92 1.00
KLA/ATP 1.04 1.01 .99 1.04 .99 1.06 1.02
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Plcg2
KLA  ATP  ATP+KLA
 NM_172285 phospholipase C, gamma 2 (Plcg2), mRNA [NM_172285] KLA .76 .74 .68 .66 .71 .92 .95
ATP .96 .90 .95 .87 .81 .79 .91
KLA/ATP .76 .71 .69 .62 .72 .78 .68
Prkca
KLA  ATP  ATP+KLA
 NM_011101 protein kinase C, alpha (Prkca), mRNA [NM_011101] KLA 1.00 .96 .94 .95 .95 .89 .96
ATP 1.00 1.03 .91 .94 .82 .87 1.13
KLA/ATP 1.02 .95 .91 .86 .78 .84 .94
Prkcb1
KLA  ATP  ATP+KLA
 NM_008855 protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] KLA .92 .95 .93 .78 .77 1.08 1.83
ATP 1.03 1.12 1.09 1.23 .90 2.08 .96
KLA/ATP .98 .99 .82 .89 .62 1.01 1.08
Prkcc
KLA  ATP  ATP+KLA
 NM_011102 protein kinase C, gamma (Prkcc), mRNA [NM_011102] KLA 1.02 1.04 1.11 1.04 .96 1.02 1.05
ATP .98 .98 1.05 1.03 1.08 .96 .95
KLA/ATP 1.21 1.16 1.09 1.07 1.04 .98 .93
Ptk2
KLA  ATP  ATP+KLA
 NM_007982 PTK2 protein tyrosine kinase 2 (Ptk2), mRNA [NM_007982] KLA .99 .99 1.02 1.04 1.09 1.22 1.57
ATP 1.04 1.09 .95 .98 .67 .96 .87
KLA/ATP .99 1.03 .87 .93 .81 1.16 1.04
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rps6kb1
KLA  ATP  ATP+KLA
 NM_001114334 ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 1, mRNA [NM_001114334] KLA .99 1.00 .90 .89 .99 .99 .92
ATP 1.01 .96 1.00 .79 1.36 1.19 .72
KLA/ATP 1.08 .99 .93 .92 1.18 .90 .56
Rps6kb1
KLA  ATP  ATP+KLA
 NM_028259 ribosomal protein S6 kinase, polypeptide 1 (Rps6kb1), transcript variant 2, mRNA [NM_028259] KLA 1.01 .93 1.07 1.04 .99 .99 .98
ATP 1.09 1.05 1.00 1.01 1.08 1.03 1.03
KLA/ATP 1.07 1.04 .94 .98 1.03 1.05 1.05
Rps6kb2
KLA  ATP  ATP+KLA
 AK090093 kidney CCL-142 RAG cDNA, RIKEN full-length enriched library, clone:G430107K15 product:ribosomal protein S6 kinase, 70kD, polypeptide 2, full insert sequence [AK090093] KLA .97 1.01 .98 .97 .98 1.04 1.07
ATP 1.00 1.08 1.06 1.09 1.11 1.06 1.03
KLA/ATP 1.05 .96 .86 1.03 1.40 1.07 .99
Rps6kb2
KLA  ATP  ATP+KLA
 NM_021485 ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), mRNA [NM_021485] KLA 1.36 1.40 1.45 1.40 1.63 1.57 1.46
ATP 1.08 1.19 .97 1.15 .90 .99 1.34
KLA/ATP 1.44 1.55 1.09 1.39 1.00 1.12 1.77
Shc1
KLA  ATP  ATP+KLA
 NM_011368 src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] KLA .88 .87 .86 .83 1.09 1.11 1.12
ATP 1.04 1.25 .85 1.17 .93 1.16 1.00
KLA/ATP .93 .96 .62 .96 .75 1.25 1.19
Shc2
KLA  ATP  ATP+KLA
 NM_001024539 src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] KLA 1.19 1.25 1.22 1.16 1.15 1.14 .98
ATP 1.04 1.14 1.15 1.53 1.29 1.06 1.09
KLA/ATP 1.26 1.24 1.26 1.49 1.31 1.30 1.30
Shc3
KLA  ATP  ATP+KLA
 NM_009167 src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] KLA 1.00 .98 1.06 1.06 1.12 1.08 1.04
ATP .99 1.02 1.00 1.05 1.00 1.08 1.08
KLA/ATP 1.08 1.06 1.01 1.06 1.03 1.12 1.41
Shc4
KLA  ATP  ATP+KLA
 NM_199022 SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] KLA 1.03 1.03 1.01 1.06 1.09 1.03 1.06
ATP .99 1.00 1.03 1.02 1.04 1.04 1.01
KLA/ATP .98 .97 1.06 1.05 1.00 1.00 1.14
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Src
KLA  ATP  ATP+KLA
 NM_009271 Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] KLA 6.99 7.23 7.54 5.99 5.34 3.39 3.00
ATP 1.02 1.06 1.06 2.08 4.41 5.03 3.97
KLA/ATP 7.44 7.51 5.48 6.24 4.86 5.86 7.90
Stat5a
KLA  ATP  ATP+KLA
 NM_011488 signal transducer and activator of transcription 5A (Stat5a), mRNA [NM_011488] KLA 8.23 8.24 6.89 4.88 4.35 1.98 1.01
ATP 1.07 1.14 1.07 1.26 3.23 3.14 1.52
KLA/ATP 8.70 9.53 7.33 6.68 4.32 2.73 1.72
Stat5b
KLA  ATP  ATP+KLA
 AK137889 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130035C01 product:unclassifiable, full insert sequence. [AK137889] KLA 1.10 1.01 .98 .90 1.03 .93 .88
ATP .90 .87 .61 .69 1.01 .97 .89
KLA/ATP 1.12 1.00 .87 .85 .95 1.07 .83
Stat5b
KLA  ATP  ATP+KLA
 NM_011489 signal transducer and activator of transcription 5B (Stat5b), transcript variant 1, mRNA [NM_011489] KLA 2.91 2.81 3.42 2.69 2.23 1.95 1.32
ATP .99 1.04 1.16 .97 1.00 1.84 2.09
KLA/ATP 2.96 3.05 3.17 2.99 1.86 1.87 3.40
Tgfa
KLA  ATP  ATP+KLA
 NM_031199 transforming growth factor alpha (Tgfa), mRNA [NM_031199] KLA 1.01 .99 1.00 1.03 1.01 1.04 1.04
ATP 1.01 1.04 1.02 1.02 1.02 1.01 1.05
KLA/ATP 1.01 1.02 1.02 1.02 1.02 1.06 1.02